CLINICAL_TRIALS
trial_result
· 2022-04-13
Clinical Trial Update: The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia [Phase 3]
Summary
A Phase 3 trial in hypertriglyceridemia assessing volanesorsen (ISIS-APOCIIIRx) has completed; results were posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Hypertriglyceridemia | Phase 3 | Status: COMPLETED | Results posted: 2022-04-13